Ondine Announces Acquisition of Exclusive License for Gold-Nanoparticle Photosensitizer

31-Jul-2008

Ondine Biopharma Corporation announced that it has acquired an exclusive license for the human therapeutic use of a gold-nanoparticle photosensitizer from UCL Business PLC, the technology transfer company of University College London, London, UK.

"In vitro studies have shown that this advanced compound is one of the most potent photodisinfection agents ever developed," stated Dr. Nicolas Loebel, Ondine's Chief Technology Officer. "The compound has proven highly efficacious in killing Methicillin/multi-drug Resistant Staphylococcus aureus, (MRSA), a prominent hospital-acquired pathogen. We intend to further develop this new agent for integration into our Photodisinfection System for various medical applications."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances